Tapeworm, vertigo and pancreatitis drugs are being trialled as COVID-19 treatments
By the Specialist Reporting Team s Alison Branley and national medical reporter Sophie Scott
Posted
SunSunday 24
updated
MonMonday 25
Australian researchers are part of global efforts to trial potential COVID-19 treatments.
(
Print text only
Cancel
With COVID-19 vaccines on their way, it s time to breathe a sigh of relief right? Well, maybe not.
Key points:
It includes drugs to treat tapeworm, pancreatitis, vertigo and cancer
Experts warn clinical trials don t always translate into effective human treatments
Most vaccines aren t 100 per cent effective and it s not likely we will achieve full coverage in the community.
Lightpoint Medical Receives CE Mark for World s First Approved Robotic Gamma Probe
News provided by
Share this article
Share this article
CHESHAM, England, Jan. 20, 2021 /PRNewswire/ Lightpoint Medical, a medical device company developing miniaturized surgical tools for advanced intra-operative cancer detection, announced today that it has received CE Mark approval for SENSEI®, the first robotic gamma probe to be commercially available to European hospital systems.
Lightpoint Medical Receives CE Mark for World’s First Approved Robotic Gamma Probe
SENSEI® has been designed for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system. The technology promises more precise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological, and prostate cancer.
Unravelling the multifaceted mechanisms of cancer cell death by mutant p53 targeting compound APR-246 medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
ANZUP Mini ASM 2020: ANZUP Trial Update - The ENZAMET Trial
(UroToday.com) The 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) featured a session on ANZUP trial updates, including an update of the critical Phase III ENZAMET trial provided by Drs. Ian Davis, Arun Azad, and Lisa Horvath.
Dr. Davis started by recapping the 2019 publication of ENZAMET.
1 This trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal anti-androgen and 563 in the enzalutamide arm. The trial schema is as follows:
The treatment groups were well balanced for all important baseline factors. In the non-steroidal anti-androgen arm, 44% of patients were planned for early docetaxel, compared to 45% in the enzalutamide arm; 53% of patients in the non-steroidal anti-androgen arm were high volume metastatic burden compared to 52% in the enza